Abstract：
A considerable debate persists in the literature about whose preferences should be considered in the calculation of quality-adjusted life-years. Some suggest considering only the preferences of the general population, while others advocate for the consideration of those of patients or a combination of both. This study aims to inform and measure the differences in health preferences between cancer patients and the general population in Quebec. A total of 60,976 observations representing the preferences of the general population for various health states were collected and used to develop a new value set using the SF-6Dv2. This value set was generated by combining 34,299 observations with time trade-off (TTO) and 26,677 observations with discrete choice experiment (DCE). Utility scores derived from this value set were compared to those of patients\' preferences from a new value set in breast and colorectal patients for the SF-6Dv2. For both patients and the general population, the \'Pain\' dimension was the highest contributor to the utility score. However, noticeable differences were observed in the estimates. Estimates of levels 2 and 3 were generally lower for cancer patients, while they were more likely to have greater estimates in severe levels. Significant differences in utility scores were also noticed with the general population showing higher mean utility scores for the same health states. These differences increased as the health states worsened. This study sheds light on the existing differences in preferences between cancer patients and the general population of Quebec for a better consideration in healthcare decision-making.
摘要：
关于在计算质量调整后的生命年时应考虑谁的偏好，文献中仍存在相当大的争论。一些人建议只考虑普通人群的偏好，而其他人则主张考虑患者或两者兼而有之。这项研究旨在告知和测量魁北克癌症患者与普通人群之间健康偏好的差异。总共收集了60,976个观察值，这些观察值代表了普通人群对各种健康状况的偏好，并用于使用SF-6Dv2开发新的值集。通过将34,299个观察值与时间权衡（TTO）和26,677个观察值与离散选择实验（DCE）相结合来生成该值集。将从该值集得出的效用得分与SF-6Dv2的乳腺和结直肠患者的新值集的患者偏好进行比较。对于患者和普通人群来说，“疼痛”维度是效用得分的最高贡献者。然而,在估计中观察到明显的差异。癌症患者的2级和3级估计值通常较低，而他们更有可能在严重水平上有更大的估计。效用得分也存在显着差异，普通人群在相同的健康状况下显示出更高的平均效用得分。这些差异随着健康状况的恶化而增加。这项研究揭示了癌症患者与魁北克普通人群之间现有的偏好差异，以便在医疗保健决策中更好地考虑。
